Bay­er ex­pands Keren­dia heart fail­ure pro­gram to 15,000 pa­tients as it plans to start three Phase III tri­als

Bay­er is work­ing on ex­pand­ing the la­bel for its chron­ic kid­ney dis­ease drug Keren­dia, an­nounc­ing three new tri­als to in­ves­ti­gate it as a treat­ment for heart fail­ure.

MOON­RAK­ER will add 9,000 new pa­tients, ex­pand­ing the clin­i­cal de­vel­op­ment pro­gram to about 15,000 par­tic­i­pants and mak­ing it one of the largest heart fail­ure study pro­grams, Bay­er claims. CPC Clin­i­cal Re­search, a non-prof­it aca­d­e­m­ic re­search or­ga­ni­za­tion af­fil­i­at­ed with the Uni­ver­si­ty of Col­orado, is con­duct­ing the Bay­er-fund­ed tri­als with oth­er in­sti­tu­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER